Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JESUS E GUTIERREZ STONE

Allopathic & Osteopathic Physicians General Practice

NPI
1396990461
CMS profile
199270
Location
ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$14.09

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $14.09 1

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JESUS E GUTIERREZ STONE

NPI 1396990461 · CMS profile ID 199270

Allopathic & Osteopathic Physicians / General Practice

ORLANDO, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396990461?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JESUS E GUTIERREZ STONE, NPI 1396990461, CMS profile ID 199270. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396990461?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JESUS E GUTIERREZ STONE, NPI 1396990461, CMS profile ID 199270. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396990461?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JESUS E GUTIERREZ STONE, NPI 1396990461, CMS profile ID 199270, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1396990461?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $14.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.0902/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737536293 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $44.05 3
PY2020 $14.09 1
PY2021 $37.05 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021
Generated from
OP_DTL_GNRL_PGYR2021_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $19,258.01 8
PY2020 Principal investigator $395,083.98 165
PY2019 Principal investigator $512,633.84 111

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

111 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ironwood Pharmaceuticals, Inc $29,828.40 12/02/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER LLC
C3718-302 No dispute reported 06/30/2026 705397529
Principal investigator 1 Eisai Inc. $4,613.00 11/26/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525501
Principal investigator 1 Eisai Inc. $2,361.00 11/26/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525503
Principal investigator 1 Eisai Inc. $4,506.00 11/26/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525505
Principal investigator 1 Eisai Inc. $2,361.00 11/26/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525509
Principal investigator 1 Eisai Inc. $2,361.00 11/26/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525511
Principal investigator 1 Ironwood Pharmaceuticals, Inc $95,564.17 11/06/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER LLC
C3718-302 No dispute reported 06/30/2026 705397527
Principal investigator 1 Eisai Inc. $4,506.00 10/29/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525491
Principal investigator 1 Eisai Inc. $2,361.00 10/29/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525493
Principal investigator 1 Eisai Inc. $4,506.00 10/29/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525495
Principal investigator 1 Eisai Inc. $2,361.00 10/29/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525497
Principal investigator 1 Eisai Inc. $4,506.00 10/29/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525499
Principal investigator 1 Ironwood Pharmaceuticals, Inc $59,697.44 09/18/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER LLC
C3718-302 No dispute reported 06/30/2026 705397525
Principal investigator 1 Eisai Inc. $4,613.00 08/27/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525359
Principal investigator 1 Eisai Inc. $2,361.00 08/27/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525361
Principal investigator 1 Eisai Inc. $2,226.00 08/27/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525363
Principal investigator 1 Eisai Inc. $2,226.00 08/27/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525365
Principal investigator 1 Eisai Inc. $2,226.00 08/15/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525367
Principal investigator 1 Eisai Inc. $4,403.00 08/15/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525369
Principal investigator 1 Eisai Inc. $4,403.00 08/15/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525371
Principal investigator 1 Eisai Inc. $2,361.00 08/15/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525435
Principal investigator 1 Eisai Inc. $384.20 08/15/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525489
Principal investigator 1 Ironwood Pharmaceuticals, Inc $23,604.82 07/19/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER LLC
C3718-302 No dispute reported 06/30/2026 705397523
Principal investigator 1 Ironwood Pharmaceuticals, Inc $81,079.44 05/17/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER LLC
C3718-302 No dispute reported 06/30/2026 705397521
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525373
Principal investigator 1 Eisai Inc. $1,094.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525375
Principal investigator 1 Eisai Inc. $1,915.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525377
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525379
Principal investigator 1 Eisai Inc. $582.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525381
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525383
Principal investigator 1 Eisai Inc. $372.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525385
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525387
Principal investigator 1 Eisai Inc. $1,715.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525389
Principal investigator 1 Eisai Inc. $1,094.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525391
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525393
Principal investigator 1 Eisai Inc. $372.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525395
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525397
Principal investigator 1 Eisai Inc. $1,094.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525399
Principal investigator 1 Eisai Inc. $1,915.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525401
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525403
Principal investigator 1 Eisai Inc. $582.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525405
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525407
Principal investigator 1 Eisai Inc. $372.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525409
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525411
Principal investigator 1 Eisai Inc. $1,715.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525413
Principal investigator 1 Eisai Inc. $1,915.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525415
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525417
Principal investigator 1 Eisai Inc. $582.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525419
Principal investigator 1 Eisai Inc. $372.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525421
Principal investigator 1 Eisai Inc. $1,715.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525423
Principal investigator 1 Eisai Inc. $1,715.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525425
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525427
Principal investigator 1 Eisai Inc. $2,361.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525429
Principal investigator 1 Eisai Inc. $2,226.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525431
Principal investigator 1 Eisai Inc. $2,361.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525433
Principal investigator 1 Eisai Inc. $3,842.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525437
Principal investigator 1 Eisai Inc. $2,361.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525439
Principal investigator 1 Eisai Inc. $3,842.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525441
Principal investigator 1 Eisai Inc. $2,361.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525443
Principal investigator 1 Eisai Inc. $3,842.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525445
Principal investigator 1 Eisai Inc. $2,361.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525447
Principal investigator 1 Eisai Inc. $1,094.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525449
Principal investigator 1 Eisai Inc. $3,842.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525451
Principal investigator 1 Eisai Inc. $1,915.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525453
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525455
Principal investigator 1 Eisai Inc. $582.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525457
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525459
Principal investigator 1 Ironwood Pharmaceuticals, Inc $28,294.27 04/17/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER LLC
C3718-302 No dispute reported 06/30/2026 705397519
Principal investigator 1 Eisai Inc. $75.00 04/04/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525461
Principal investigator 1 Eisai Inc. $2,226.00 04/04/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525463
Principal investigator 1 Eisai Inc. $1,715.00 04/04/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525465
Principal investigator 1 Eisai Inc. $1,094.00 04/04/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525467
Principal investigator 1 Eisai Inc. $4,403.00 04/04/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525469
Principal investigator 1 Eisai Inc. $3,107.00 04/04/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525471
Principal investigator 1 Eisai Inc. $2,361.00 04/04/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525473
Principal investigator 1 Eisai Inc. $3,842.00 04/04/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525475
Principal investigator 1 Eisai Inc. $75.00 04/04/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525477
Principal investigator 1 Eisai Inc. $1,915.00 04/04/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525479
Principal investigator 1 Eisai Inc. $75.00 04/04/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525481
Principal investigator 1 Eisai Inc. $582.00 04/04/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525483
Principal investigator 1 Eisai Inc. $75.00 04/04/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525485
Principal investigator 1 Eisai Inc. $372.00 04/04/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525487
Principal investigator 1 Eisai Inc. $1,715.00 03/12/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525353
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525355
Principal investigator 1 Eisai Inc. $3,842.00 03/12/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525357
Principal investigator 1 Eisai Inc. $1,715.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525317
Principal investigator 1 Eisai Inc. $1,094.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525319
Principal investigator 1 Eisai Inc. $1,715.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525321
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525323
Principal investigator 1 Eisai Inc. $4,403.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525325
Principal investigator 1 Eisai Inc. $1,767.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525327
Principal investigator 1 Eisai Inc. $3,107.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525329
Principal investigator 1 Eisai Inc. $2,396.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525331
Principal investigator 1 Eisai Inc. $1,767.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525333
Principal investigator 1 Eisai Inc. $2,361.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525335
Principal investigator 1 Eisai Inc. $1,915.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525337
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525339
Principal investigator 1 Eisai Inc. $582.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525341
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525343
Principal investigator 1 Eisai Inc. $1,715.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525345
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525347
Principal investigator 1 Eisai Inc. $1,715.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525349
Principal investigator 1 Eisai Inc. $75.00 01/24/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525351
Principal investigator 1 Ironwood Pharmaceuticals, Inc $500.00 01/11/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER LLC
C3718-302 No dispute reported 06/30/2026 705397515
Principal investigator 1 Eisai Inc. $1,715.00 01/08/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525305
Principal investigator 1 Eisai Inc. $75.00 01/08/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525307
Principal investigator 1 Eisai Inc. $1,715.00 01/08/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525309
Principal investigator 1 Eisai Inc. $75.00 01/08/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525311
Principal investigator 1 Eisai Inc. $4,613.00 01/08/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525313
Principal investigator 1 Eisai Inc. $2,361.00 01/08/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702525315
Principal investigator 1 Ironwood Pharmaceuticals, Inc $16,604.10 01/04/2019 Non-covered Recipient Entity
GUTIERREZ MEDICAL CENTER LLC
C3718-302 No dispute reported 06/30/2026 705397517